These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38594748)

  • 1. A phenotypic screening approach to target p60AmotL2-expressing invasive cancer cells.
    Fonseca P; Cui W; Struyf N; Tong L; Chaurasiya A; Casagrande F; Zhao H; Fernando D; Chen X; Tobin NP; Seashore-Ludlow B; Lundqvist A; Hartman J; Göndör A; Östling P; Holmgren L
    J Exp Clin Cancer Res; 2024 Apr; 43(1):107. PubMed ID: 38594748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering the Role of p60AmotL2 in Epithelial Extrusion and Cell Detachment.
    Cui W; Subramani A; Fonseca P; Zhang Y; Tong L; Zhang Y; Egevad L; Lundqvist A; Holmgren L
    Cells; 2023 Aug; 12(17):. PubMed ID: 37681890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of E-Cadherin Function through the AmotL2 Isoforms Promotes Ameboid Cell Invasion.
    Subramani A; Cui W; Zhang Y; Friman T; Zhao Z; Huang W; Fonseca P; Lui WO; Narayanan V; Bobrowska J; Lekka M; Yan J; Conway DE; Holmgren L
    Cells; 2023 Jun; 12(13):. PubMed ID: 37443716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
    Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
    Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine β-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer.
    Druzhyna N; Szczesny B; Olah G; Módis K; Asimakopoulou A; Pavlidou A; Szoleczky P; Gerö D; Yanagi K; Törö G; López-García I; Myrianthopoulos V; Mikros E; Zatarain JR; Chao C; Papapetropoulos A; Hellmich MR; Szabo C
    Pharmacol Res; 2016 Nov; 113(Pt A):18-37. PubMed ID: 27521834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of lysosome-targeting drugs with anti-inflammatory activity as potential invasion inhibitors of treatment resistant HER2 positive cancers.
    Hansen MB; Postol M; Tvingsholm S; Nielsen IØ; Dietrich TN; Puustinen P; Maeda K; Dinant C; Strauss R; Egan D; Jäättelä M; Kallunki T
    Cell Oncol (Dordr); 2021 Aug; 44(4):805-820. PubMed ID: 33939112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BET inhibitor suppresses melanoma progression
    Deng G; Zeng F; Su J; Zhao S; Hu R; Zhu W; Hu S; Chen X; Yin M
    Theranostics; 2020; 10(25):11428-11443. PubMed ID: 33052224
    [No Abstract]   [Full Text] [Related]  

  • 8. [Identification of a new pro-invasion factor in tumor microenvironment: progress in function and mechanism of extracellular ATP].
    Fang WG; Tian XX
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 49(2):188-195. PubMed ID: 28416823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer.
    Mertens S; Huismans MA; Verissimo CS; Ponsioen B; Overmeer R; Proost N; van Tellingen O; van de Ven M; Begthel H; Boj SF; Clevers H; Roodhart JML; Bos JL; Snippert HJG
    Cell Rep; 2023 Apr; 42(4):112324. PubMed ID: 37000626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
    Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
    J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET Inhibitors Potentiate Chemotherapy and Killing of
    Tan X; Tong J; Wang YJ; Fletcher R; Schoen RE; Yu J; Shen L; Zhang L
    Cancer Res; 2019 Mar; 79(6):1191-1203. PubMed ID: 30674532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dehydropeptidase 1 promotes metastasis through regulation of E-cadherin expression in colon cancer.
    Park SY; Lee SJ; Cho HJ; Kim TW; Kim JT; Kim JW; Lee CH; Kim BY; Yeom YI; Lim JS; Lee Y; Lee HG
    Oncotarget; 2016 Feb; 7(8):9501-12. PubMed ID: 26824987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression.
    Shi C; Yang EJ; Liu Y; Mou PK; Ren G; Shim JS
    Oncogene; 2021 Feb; 40(5):937-950. PubMed ID: 33293694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression.
    Paschall AV; Zimmerman MA; Torres CM; Yang D; Chen MR; Li X; Bieberich E; Bai A; Bielawski J; Bielawska A; Liu K
    BMC Cancer; 2014 Jan; 14():24. PubMed ID: 24422988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BET bromodomain is a novel regulator of TAZ and its activity.
    Duan Q; Xiao Y; Zhu L; Liu Z; Mao X; Zhou Z; Liao C; Cai J; Huang F; Liu Z; Zeng J; Xia K; Chang C; Qi J; Chen Z; Huang H; Yang T
    Biochim Biophys Acta; 2016 Dec; 1859(12):1527-1537. PubMed ID: 27717711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.
    Xu H; Yu Y; Marciniak D; Rishi AK; Sarkar FH; Kucuk O; Majumdar AP
    Mol Cancer Ther; 2005 Mar; 4(3):435-42. PubMed ID: 15767552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. lincRNA-p21 Mediates the Anti-Cancer Effect of Ginkgo Biloba Extract EGb 761 by Stabilizing E-Cadherin Protein in Colon Cancer.
    Chang L; Liu T; Chai Z; Jie S; Li Z; Liu M; Dong W; Wang X; Zhou B
    Med Sci Monit; 2018 Dec; 24():9488-9496. PubMed ID: 30594943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
    Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK
    Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphatic Invasion of Plakoglobin-Dependent Tumor Cell Clusters Drives Formation of Polyclonal Lung Metastases in Colon Cancer.
    Küçükköse E; Laoukili J; Gorelick AN; Degner S; Laclé MM; van den Bent L; Peters NA; Verheem A; Hung WT; Frenkel NC; Wassenaar ECE; Lansu N; Lenos KJ; Vermeulen L; Koopman M; Roodhart JML; Kops GJPL; Borel Rinkes IHM; Hagendoorn J; Naxerova K; Kranenburg O
    Gastroenterology; 2023 Aug; 165(2):429-444.e15. PubMed ID: 36906044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.